It’s the one-two punch cancer treatment that ‘floats like a butterfly, and STINGs like a bee’! – WEHI (Walter and Eliza Hall Institute of Medical Research)
WEHI (Walter and Eliza Hall Institute of Medical Research) made the foll0wing post on LinkedIn:
“It’s the one-two punch cancer treatment that ‘floats like a butterfly, and STINGs like a bee’!
WEHI researchers have revealed that a novel combination of two existing cancer drugs shows great potential as a future treatment for patients with acute myeloid leukaemia (AML), one of the most common types of blood cancer.
The combination of cancer drug venetoclax and a STING agonist (an emerging class of immunotherapy drugs) was found to be highly effective in killing AML cancer cells in lab-based tests.
Critically, the combination treatment showed great promise in AML samples that contain a mutated p53 protein, a type of AML that is generally more aggressive and harder to treat.
The discovery, published today in Cancer Cell (Cell Press), could soon lead to clinical trials, providing hope for the 1100 Australians diagnosed with this disease annually.
Our researchers and clinicians are now translating these highly promising findings into a new clinical trial in AML patients in collaboration with Melbourne-based Aculeus Therapeutics, a biotechnology company with a proprietary STING agonist.
This research was led by Dr. Sarah Diepstraten, Professor Andreas Strasser, Professor Andrew Wei and Associate Professor Gemma Kelly, with support from the VCA, National Health and Medical Research Council (NHMRC), and Medical Research Future Fund.
Learn more.
Read the study.”
Source: WEHI (Walter and Eliza Hall Institute of Medical Research)/LinkedIn
OncoDaily
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023